Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glargine vs NPH Insulin for Diabetes in Pregnancy
NCT06619301Phase 3Recruiting
- Sponsor
- Loyola University Chicago
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in gestational diabetes mellitus (GDM) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Loyola University Chicago. Primary endpoint: Hypoglycemia. Started Apr 2024; status: recruiting.
02
Drugs
insulin glargine
03
Conditions
gestational diabetes mellitus (GDM)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06619301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619301.